Wilbert B. Copeland

959 total citations
8 papers, 249 citations indexed

About

Wilbert B. Copeland is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Wilbert B. Copeland has authored 8 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Wilbert B. Copeland's work include Multiple Myeloma Research and Treatments (4 papers), Chemokine receptors and signaling (3 papers) and Acute Myeloid Leukemia Research (2 papers). Wilbert B. Copeland is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Chemokine receptors and signaling (3 papers) and Acute Myeloid Leukemia Research (2 papers). Wilbert B. Copeland collaborates with scholars based in United States, Italy and United Kingdom. Wilbert B. Copeland's co-authors include Herbert M. Sauro, Deepak Chandran, Sean C. Sleight, Bryan Bartley, Michal Galdzicki, Costas D. Maranas, Alessandro Previtali, James D. Cavenagh, C.L. Beach and Shelonitda Rose and has published in prestigious journals such as Blood, Scientific Reports and Metabolic Engineering.

In The Last Decade

Wilbert B. Copeland

8 papers receiving 248 citations

Peers

Countries citing papers authored by Wilbert B. Copeland

Since Specialization

Citations

This map shows the geographic impact of Wilbert B. Copeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilbert B. Copeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilbert B. Copeland more than expected).

Fields of papers citing papers by Wilbert B. Copeland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilbert B. Copeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilbert B. Copeland. The network helps show where Wilbert B. Copeland may publish in the future.

Co-authorship network of co-authors of Wilbert B. Copeland

This figure shows the co-authorship network connecting the top 25 collaborators of Wilbert B. Copeland. A scholar is included among the top collaborators of Wilbert B. Copeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilbert B. Copeland. Wilbert B. Copeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma 2021 ·Scientific Reports ·Mary H. Young, (unknown), Elizabeth Whalen, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Kathryn J. Newhall	5
2	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML 2021 ·Blood Advances ·Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, (unknown), Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman	64
3	Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study 2019 ·Blood ·Amer M. Zeidan, James D. Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac W. Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, (unknown), Shelonitda Rose, C.L. Beach, Lewis R. Silverman	60
4	Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status 2018 ·Blood ·(unknown), Mark Tometsko, Wilbert B. Copeland, Elizabeth Whalen, Frank Schmitz, Ethan Thompson, Amit Agarwal, Teresa M. Foy, (unknown), Vitalina Komashko, (unknown), Brian A. Fox, Kathryn J. Newhall	3
5	Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma 2018 ·Blood ·Mary H. Young, (unknown), Alison Fitch, Frank Schmitz, Jake Gockley, Mark McConnell, David J. Reiss, Wilbert B. Copeland, Sadie Johnson, (unknown), Robert M. Hershberg, (unknown), Alexander V. Ratushny, Brian A. Walker, Andrew Dervan, Gareth J. Morgan	2
6	Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies 2017 ·Blood ·Samuel A. Danziger, Andrew Dervan, Frank Schmitz, Brian A. Walker, Wilbert B. Copeland, Alison Fitch, Kathryn J. Newhall, Cody Ashby, Michael Bauer, Bart Barlogie, (unknown), Matthew Trotter, (unknown), Alexander V. Ratushny, Gareth J. Morgan	1
7	Computational tools for metabolic engineering 2012 ·Metabolic Engineering ·Wilbert B. Copeland, Bryan Bartley, Deepak Chandran, Michal Galdzicki, (unknown), Sean C. Sleight, Costas D. Maranas, Herbert M. Sauro	76
8	Mathematical modeling and synthetic biology 2008 ·Drug Discovery Today Disease Models ·Deepak Chandran, Wilbert B. Copeland, Sean C. Sleight, Herbert M. Sauro	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact